Energy-Based Devices Work Well for Feminine Rejuvenation

Share this content:
Energy-Based Devices Work Well for Feminine Rejuvenation
Energy-Based Devices Work Well for Feminine Rejuvenation

TUESDAY, April 3, 2018 (HealthDay News) -- Energy-based devices are both safe and effective methods of nonsurgical treatment for feminine rejuvenation, according to a review published online March 10 in the Journal of Cosmetic Dermatology.

Michael Gold, M.D., from the Gold Skin Care Center in Nashville, Tenn., and colleagues conducted a literature review to explore the safety, efficacy, tolerability, patient satisfaction, and clinical usability of technologies for feminine rejuvenation. Such technologies include minimally ablative fractional laser and radiofrequency.

The researchers found that energy-based devices may induce wound healing, stimulating new collagen and elastin fiber formation. Radiofrequency treatment increased small nerve fiber density in the papillary dermis, which may improve nerve sensitivity and sexual function, including arousal and orgasmic dysfunction. Mild-to-moderate primary or secondary vulvovaginal laxity and associated secondary conditions have been effectively treated using both minimally ablative fractional laser and radiofrequency. Both have been reported safe, effective, and well tolerated with a rapid return to activities of daily living.

"Studies and clinical experience suggest that feminine genital rejuvenation using energy-based devices seems an attractive option for patients with mild-to-moderate medical conditions," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »